应用2024年国际胰腺病协会指南通过CT和MRI识别疑似导管内乳头状黏液性肿瘤中的(前)恶性病变
回顾性分析181例术前增强CT和129例术前增强MRI的疑似导管内乳头状黏液性肿瘤,评估2024年国际胰腺病协会指南中所有高危征象和令人担忧特征,并建立列线图识别(前)恶性病变。在独立测试队列中,CT和MRI列线图诊断性能优于2017年指南的高危征象(准确率:CT 77.9% vs 67.7%,p=0.039;MRI 75.5% vs 59.2%,p=0.021)及基于2017版的六分量表(AUC:CT 0.808 vs 0.726,p=0.039;MRI 0.865 vs 0.631,p<0.001)。
要点
- 2024年IAP指南相关征象联合列线图在CT和MRI上均可有效识别疑似IPMN中的(前)恶性病变。
- CT和MRI列线图诊断准确率与AUC均优于2017年IAP指南高危征象及六分量表。
- CT与MRI对多数征象的一致性为中等至优秀,仅囊壁增厚强化除外。
核心结论
- 基于2024年IAP指南的列线图在CT和MRI评估中均能有效识别疑似IPMN中的(前)恶性病变,且在测试队列中较2017版有改善。
研究设计与样本
- 回顾性分析181例术前增强CT和129例术前增强MRI的疑似IPMN,评估2024年IAP指南所有高危征象和令人担忧特征,采用多变量逻辑回归建立列线图,并在独立测试队列中验证及与2017年IAP指南比较。
关键影像表现/征象
- 血清CA19-9升高、主胰管≥10 mm、囊壁增厚强化、壁结节或实性成分强化、淋巴结肿大与CT和MRI检出的(前)恶性相关。
- 主胰管≥5 mm及主胰管管径突然变化伴远端萎缩也与CT检出的(前)恶性相关。
- CT与MRI对多数征象的一致性为中等至优秀,囊壁增厚强化除外。
诊断标准与关键数值
- CT列线图在测试队列的准确率为77.9%,高于2017年IAP指南高危征象的67.7%(p=0.039)。
- MRI列线图在测试队列的准确率为75.5%,高于2017年IAP指南高危征象的59.2%(p=0.021)。
- CT列线图在测试队列的AUC为0.808,高于基于2017版六分量表的0.726(p=0.039)。
- MRI列线图在测试队列的AUC为0.865,高于基于2017版六分量表的0.631(p<0.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: To evaluate the diagnostic performance of the 2024 International Association of Pancreatology (IAP) guidelines for presumed intraductal papillary mucinous neoplasms (IPMNs).
MATERIALS AND METHODS: We retrospectively analyzed 181 presumed IPMNs with preoperative contrast-enhanced CT and 129 presumed IPMNs with preoperative contrast-enhanced MRI. All high-risk stigmata (HRS) and worrisome features (WF) in the 2024 IAP guidelines were assessed. Multivariable logistic regression analysis developed nomograms for identifying (pre)malignancy among presumed IPMNs via CT and MRI. The diagnostic performance of nomograms was validated and compared with the 2017 IAP guidelines in independent testing cohorts.
RESULTS: Elevated serum carbohydrate antigen 19-9, main pancreatic duct (MPD) ≥ 10 mm, thickened enhancing cyst wall, enhanced mural nodule or solid component, and lymphadenopathy were associated with (pre)malignancy via CT and MRI. MPD ≥ 5 mm and abrupt MPD caliber changes with distal atrophy were also related to (pre)malignancy via CT. Both the CT and MRI nomograms demonstrated satisfactory and improved diagnostic performance compared to HRS in the 2017 IAP guidelines (accuracy: 77.9% vs 67.7%, p = 0.039 for CT and 75.5% vs 59.2%, p = 0.021 for MRI) and the six-point scale based on the 2017 version (AUC: 0.808 vs 0.726, p = 0.039 for CT and 0.865 vs 0.631, p < 0.001 for MRI) in the testing cohorts. The intermodality agreement between CT and MRI was moderate to excellent, except for thickened enhancing cyst wall.
CONCLUSION: The nomograms based on the 2024 IAP guidelines effectively identified (pre)malignant lesions among presumed IPMNs and demonstrated improvement over the 2017 version when evaluated via both CT and MRI in the testing cohorts.
引用
- Deng W, Yang C, Cong F, et al. Application of the 2024 International Association of Pancreatology Guidelines for Identifying (Pre)Malignancy Among Presumed Intraductal Papillary Mucinous Neoplasms via CT and MRI. Acad Radiol. 2025. PMID: 40541552. doi:10.1016/j.acra.2025.05.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。